Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GONEXT phase II trial of sorafenib plus GEMOX in unresectable hepatocellular carcinoma
2008-000123-26Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- May 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib, gemcitabine and oxaliplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Progression-free survival. Started May 2008; status: completed.
02
Drugs
sorafenibgemcitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-000123-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000123-26.